Skip to content
approvedCognitive & Neuro

Cortexin

Also known as: Кортексин, Cortexinum, Brain cortex polypeptide complex

Cortexin is a polypeptide complex derived from the cerebral cortex of cattle or pigs, containing a mixture of low-molecular-weight neuropeptides, amino acids, vitamins, and trace minerals. It has been approved in Russia and several CIS countries for the treatment of various neurological conditions including stroke recovery, traumatic brain injury, cognitive impairment, and childhood neurodevelopmental disorders. While widely prescribed in post-Soviet medicine, Cortexin lacks the rigorous randomized controlled trials expected by Western regulatory standards.

3 cited references·5 researched benefits

Quick Answer

Cortexin is a polypeptide complex extracted from animal brain cortex, approved in Russia and CIS countries for neurological conditions including stroke, traumatic brain injury, and cognitive decline. It contains neuropeptides, amino acids, and micronutrients that collectively support neuronal survival, reduce oxidative stress, and modulate neurotransmitter activity. Clinical use spans over two decades in Russia, though Western-standard randomized controlled trials remain limited.

Key Facts

Mechanism
Cortexin contains a complex mixture of neuropeptides (molecular weight below 10 kDa) that exert multiple synergistic effects on the central nervous system. The proposed mechanisms include: direct neurotrophic support through peptide signaling that promotes neuronal survival and differentiation; antioxidant activity that reduces free radical damage in ischemic and traumatic brain injury; modulation of GABAergic and glutamatergic neurotransmission to restore excitatory/inhibitory balance; stabilization of neuronal membranes; and enhancement of intracellular protein synthesis in neurons. The polypeptide fraction is thought to mimic endogenous neuropeptide signaling, effectively providing exogenous neurotrophic support to damaged or aging brain tissue. Because it is a mixture rather than a single molecule, the precise molecular targets and signaling pathways are not fully characterized.
Research Status
approved
Half-Life
Variable (polypeptide complex; individual components have different half-lives)
Molecular Formula
Complex mixture (MW < 10 kDa)
Primary Use
Cognitive & Neuro
Table of Contents

Benefits

  • Stroke recovery support — clinical studies in Russia show improved neurological outcomes and faster functional recovery when Cortexin is added to standard post-stroke rehabilitation protocolsmoderate
  • Neuroprotection in traumatic brain injury — reduces secondary neuronal damage through antioxidant and anti-inflammatory mechanisms in clinical and preclinical modelsmoderate
  • Cognitive improvement in elderly patients — improves memory, attention, and overall cognitive function scores in patients with age-related cognitive decline and mild cerebrovascular diseasemoderate
  • Pediatric neurodevelopmental support — used in Russia for speech delay, minimal brain dysfunction, and cerebral palsy in children, with clinical reports of improved developmental milestonespreliminary
  • Seizure threshold modulation — some evidence of anticonvulsant properties, with clinical use as adjunctive therapy in epilepsy managementpreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intramuscular injection10 mg daily (adults); 5 mg daily (children)Once daily for 10-day coursesStandard approved dosing in Russia. Reconstitute lyophilized powder with 1–2 mL of 0.5% procaine or normal saline. Courses are repeated 2–4 times per year with intervals of 3–6 months.
Intramuscular injection (acute conditions)10–20 mg daily (adults)Once or twice daily for 10 daysHigher doses used in acute neurological conditions such as ischemic stroke or TBI. In critical care settings, doses up to 20 mg per day have been used under medical supervision.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Injection site reactions — pain, redness, or swelling at the intramuscular injection sitecommon
  • Allergic reactions — hypersensitivity reactions possible due to the animal-derived protein content; contraindicated in individuals with known allergies to animal proteinsrare
  • Headache — transient headache reported in some patients during the initial course of treatmentrare
  • Prion disease risk (theoretical) — as an animal brain-derived product, theoretical concerns about transmissible spongiform encephalopathies exist, though no cases have been reportedserious

Frequently Asked Questions

How does Cortexin compare to Cerebrolysin?
Both Cortexin and Cerebrolysin are animal-derived peptide complexes used for neuroprotection, but they differ in source and composition. Cerebrolysin is derived from pig brain tissue and has been studied in larger international clinical trials, including for Alzheimer's disease and stroke. Cortexin is derived from cattle or pig cerebral cortex and is used more broadly in Russian/CIS clinical practice for a wider range of neurological conditions. Cerebrolysin is administered intravenously, while Cortexin is given intramuscularly. Both lack FDA approval, but Cerebrolysin has somewhat more extensive international clinical trial data.
Is Cortexin available outside of Russia?
Cortexin is primarily available in Russia, Belarus, Kazakhstan, and other CIS countries where it is an approved pharmaceutical product. It is not available as a prescription drug in the US, EU, or most Western countries. Some individuals obtain it through international pharmacies or import it for personal use, but this is subject to each country's import regulations for prescription pharmaceuticals. There are no current plans to pursue FDA or EMA approval.
Is there a risk of prion disease from Cortexin?
The theoretical risk of prion disease transmission from animal brain-derived products is a legitimate scientific concern, and it is one of the reasons Western regulators are cautious about such products. However, Cortexin's manufacturing process involves hydrolysis and purification steps that reduce the prion protein content, and no cases of transmissible spongiform encephalopathy have been attributed to Cortexin use over decades of clinical use in Russia. The manufacturer certifies that source animals are screened and that production meets safety standards, though these may differ from Western regulatory requirements.

References

  1. 1
    Cortexin in the treatment of ischemic stroke: clinical and neurophysiological study(2006)PubMed ↗
  2. 2
    Neuroprotective effects of cortexin in a model of incomplete global cerebral ischemia in rats(2010)PubMed ↗
  3. 3
    Clinical efficacy and safety of cortexin in cognitive disorders of vascular and neurodegenerative origin(2015)PubMed ↗

Latest Research

Last updated: 2026-02-19